OBJECTIVE: To determine whether methadone, buprenorphine, or detoxification treatment is the most cost-effective approach to the management of opioid use disorder (OUD) during pregnancy. STUDY DESIGN: A decision analytic model compared the cost-effectiveness of initiation of methadone, buprenorphine, or detoxification in treating OUD during pregnancy. Women were assumed to be appropriate candidates for all three treatment strategies. Probabilities, costs, and utilities were determined from the existing literature. Incremental cost-effective ratios (ICERs) for each strategy were calculated and an ICER of $100,000/QALY was used to define cost effectiveness. One-way sensitivity analyses and a Monte Carlo probabilistic sensitivity analysis were performed. RESULTS: Using baseline estimates, initiation of buprenorphine was more effective at a lower cost than either methadone or detoxification; thus, detoxification was dominated by both methadone and buprenorphine (Table) . Based on a nationwide estimate of 20,000 pregnant women affected by OUD annually, buprenorphine use led to a cost savings of 179 million dollars when compared to methadone and 1.49 billion dollars when compared to detoxification. In one-way sensitivity analyses, methadone became the most costeffective strategy when the medication cost of buprenorphine exceeded 337 dollars/month (169% of the base case estimate) or if the incidence of relapse among women on buprenorphine was higher than 35% (422% of the base case estimate). Monte Carlo analyses revealed that buprenorphine was always cost-effective compared with the other strategies and dominated the other strategies 99.7% of the time. CONCLUSION: Buprenorphine is more cost-effective than either methadone or detoxification as treatment for OUD during pregnancy when all treatment options are medically appropriate. This finding was robust in sensitivity analyses.
OBJECTIVE: To determine whether methadone, buprenorphine, or detoxification treatment is the most cost-effective approach to the management of opioid use disorder (OUD) during pregnancy. STUDY DESIGN: A decision analytic model compared the cost-effectiveness of initiation of methadone, buprenorphine, or detoxification in treating OUD during pregnancy. Women were assumed to be appropriate candidates for all three treatment strategies. Probabilities, costs, and utilities were determined from the existing literature. Incremental cost-effective ratios (ICERs) for each strategy were calculated and an ICER of $100,000/QALY was used to define cost effectiveness. One-way sensitivity analyses and a Monte Carlo probabilistic sensitivity analysis were performed. RESULTS: Using baseline estimates, initiation of buprenorphine was more effective at a lower cost than either methadone or detoxification; thus, detoxification was dominated by both methadone and buprenorphine (Table) . Based on a nationwide estimate of 20,000 pregnant women affected by OUD annually, buprenorphine use led to a cost savings of 179 million dollars when compared to methadone and 1.49 billion dollars when compared to detoxification. In one-way sensitivity analyses, methadone became the most costeffective strategy when the medication cost of buprenorphine exceeded 337 dollars/month (169% of the base case estimate) or if the incidence of relapse among women on buprenorphine was higher than 35% (422% of the base case estimate). Monte Carlo analyses revealed that buprenorphine was always cost-effective compared with the other strategies and dominated the other strategies 99.7% of the time. CONCLUSION: Buprenorphine is more cost-effective than either methadone or detoxification as treatment for OUD during pregnancy when all treatment options are medically appropriate. This finding was robust in sensitivity analyses. STUDY DESIGN: This is a population-based retrospective cohort study using National Vital Statistics data. All women covered by Medicaid who delivered singleton gestations and had pregestational DM coded on the birth certificate in states using the 2003 birth certificate revision were included. We classified states as "expanded" if they implemented expansion programs in 2014. We compared maternal and neonatal outcomes in 2013 (before policy changes) and 2015 (1 year after Medicaid expansion was enacted) using a difference-indifferences approach to account for secular trends in outcomes unrelated to Medicaid expansion. We then constructed a multilevel model to investigate the association of Medicaid expansion with outcomes adjusted for age, race, education, parity, and clustering by state. RESULTS: Of 27,113 women who delivered during the study period, 12,795 (47.2%) were in states that expanded Medicaid. First trimester prenatal care entry was more common in 2015 than in 2013 in both expanded states (+4.6%) and non-expanded states (+3.4%), and was not associated with Medicaid expansion (adjusted odds ratio (aOR) 1.09, 95% CI 0.94-1.27). Primary cesarean delivery was less common in 2015 than in 2013 in both expanded (-0.8%) and non-expanded states (-0.9%), and these differences were not associated with Medicaid expansion (aOR 1.00, 95% CI 0.89-1.14).
Although fewer infants were large-for-gestational age in 2015 than in 2013 in both expanded (-1.0%) and non-expanded states (-0.6%), frequency of neonatal morbidity (NICU admission at term, NICU admission overall, and >6 hours of respiratory support) increased over the study period; these changes were all independent of Medicaid expansion. (Table) CONCLUSION: Medicaid expansion was not associated with differences in early prenatal care, maternal or neonatal outcomes among women with pregestational DM. Access to preconception care is necessary, but insurance access alone may not be sufficient to improve outcomes in this population. OBJECTIVE: Current postpartum (PP) venous thromboembolism (VTE) prophylaxis (ppx) recommendations are based on consensus and expert opinion. PP VTE can result in morbidity and mortality, but it is a rare event. We compare the cost-effectiveness of three PP VTE ppx strategies in a general obstetric population. STUDY DESIGN: We constructed a decision analytic tree to model a population of women in the US under consideration for PP VTE ppx from a health care institution perspective. We considered three strategies: 1) mechanical ppx alone 2) RCOG risk-based protocol and 3) our local risk-based protocol (UAB). We assumed mechanical ppx would be used for all strategies and enoxaparin (LMWH) administered per strategy protocol (broad use for RCOG and narrow use for UAB). Patients with indications for therapeutic anticoagulation were excluded. Model inputs for probability and cost were derived from existing literature. Primary outcome was incremental cost per VTE/pulmonary embolus (PE) death prevented. Secondary outcomes included VTE, PE, death from bleeding attributable to heparin, wound hematoma and heparin-induced thrombocytopenia (HIT). A cost-benefit table was constructed using probabilistic estimates of outcomes and costs in a population of 100,000. One-and two-way sensitivity and probabilistic analyses were performed to explore parametric uncertainty. RESULTS: The incremental cost effectiveness of the UAB and RCOG protocols were $348,385 and $1,069,310 per VTE/PE death prevented, respectively. Mechanical ppx alone was less expensive and less effective than the UAB and RCOG protocols in preventing VTE, PE, and VTE/PE death, but resulted in fewer cases of wound hematoma and HIT (Table) . Incremental costs of UAB and RCOG protocols were considerable (Table) . In probabilistic analysis, mechanical ppx alone was cost-saving in 85% of 100,000 Monte Carlo simulations with the UAB protocol cost-saving in 15%. One-and two-way analyses showed that the UAB protocol is cost-saving if baseline VTE risk is >1.3%, VTE/PE death cost is >$544,457, PE cost is >$80,196, or LMWH cost is <$20.29. Regardless of LMWH cost, the RCOG protocol is never cost-saving ( Figure) . CONCLUSION: Risk-based PP VTE ppx protocols reduce the risk of VTE, PE, and VTE-related death, but are considerably costlier than mechanical ppx alone and result in more heparin-related adverse events.
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